Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 4, 2006, Pages 483-490

  Carr, Jocelyn L ^a   Tingle, Malcolm D ^a   McKeage, Mark J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Biotransformation; Heme proteins; HPLC ICPMS; JM118; Platinum drugs; Satraplatin

Indexed keywords

CARBON MONOXIDE; CYTOCHROME C; GLUTATHIONE; HEME; HEMOGLOBIN; HEMOPROTEIN; IRON DERIVATIVE; METHEMOGLOBIN; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SATRAPLATIN;

ABSORPTION SPECTROPHOTOMETRY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; MASS SPECTROMETRY; MONITORING; OXIDATION; PRIORITY JOURNAL; PROTEIN FUNCTION; TIME;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOCHROMES C; ELECTRON TRANSPORT; GLUTATHIONE; HALF-LIFE; HEMEPROTEINS; HEMOGLOBINS; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; NAD; ORGANOPLATINUM COMPOUNDS; OXIDATION-REDUCTION;

EID: 30644462974     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0069-5     Document Type: Article

References (33)

1. Ando Y, Shimizu T, Nakamura K, Mushiroda T, Nakagawa T, Kodama T, Kamataki T (1998) Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br J Cancer 78:1170-1174
2. 2 and their reduction products with PM2 DNA. Biochemistry 23:4817-4820
3. Carr JL, Tingle MD, McKeage MJ (2002) Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 50:9-15
4. Cashon R, Bonaventura C, Bonaventura J (1986) The nicotinamide adenine dinucleotides as allosteric effectors of human haemoglobin. J Biol Chem 261:12700-12705
5. Chaney SG, Wyrick S, Kaun Till G (1990) In vitro biotransformations of tetrachloro(d,1,-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res 50:4539-4545
6. Choi S, Filotto C, Bisanzo M, Delaney S, Lagasee D, Whitworth JL, Jusko A, Li C, Wood NA, Willingham J, Schwenker A, Spaulding K (1998) Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 37:2500-2504
7. Eastman A (1987) Glutathione-mediated activation of anti-cancer platinum(IV) complexes. Biochem Pharmacol 36:4177-4178
8. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886
9. Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C, Smith IE (1999) Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17:3822
10. Galettis P, Carr JL, Paxton JW, McKeage MJ (1999) Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal Atom Spectrom 14:953-956
11. 14C-JM118 in rats and dogs (abstract). Proc Am Assoc Cancer Res 39:525
12. Gill HJ, Tingle MD, Park K (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40:531-538
13. Gibson GG, Skett P (1994) Techniques and experiments illustrating drug metabolism Chapter 8 In: Introduction to drug metabolism 2nd edn. Chapman and Hill, Glasgow, pp 217-257
14. Guidotti G, Konigsberg W (1967) The characterization of modified human haemoglobin iodoacetamide and N-ethylmaleimide. J Biol Chem 239:1474-1484
15. 2], a metabolite of an orally active platinum anticancer drug. J Am Chem Soc 114:5646-5654
16. Hildebrandt A, Estabrook RW (1971) Evidence for the participation of cytochrome b5 in hepatic microsomal mixed-function oxidation reactions. Arch Biochem Biophys 143:66-79
17. Kelland LR (2000) An Update on Satraplatin: The first orally available platinum anticancer drug. Expert Opin Inv Drug 9:1373-1382
18. Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, Peereboom D (2005) Phase II study of oral bis(acetate) ammine dichloro (cyclohexylamine) platinum (IV) (JM216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drug 23:79-84
19. Lemma K, Sargeson AM, Elding LI (2000) Kinetics and mechanism for reduction of oral anticancer platinum(IV) di-carboxylate compounds by L-ascorbate ions. J Chem Soc (Dalton Trans), pp 1167-1172
20. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan S, Murrer BA, Santabarbara P, Harrap KR, Judson IR (1995) A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451-458
21. Piantadosi CA (2002) Biological chemistry of carbon monoxide. Antioxid Redox Sign 4:259-270
22. Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF (1995) Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J Pharm Biomed Anal 13:1493-1498
23. Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR (1996a) Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1-6
24. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CFJ, Murrer BA, Harrap KR. (1996b) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155-162
25. Raynaud FI, Odell DE, Kelland LR (1996c) Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione level. Br J Cancer 73:380-386
26. Salemme FR (1977) Structure and function of cytochromes c. Ann Rev Biochem 46:299-329
27. Salvati AM, Tentori L. (1981) Determination of aberrant haemoglobin derivatives in human blood. Methods Enzymol 76:715-733
28. Sargent F (1947) A study of the normal distribution of ascorbic acid between the red cells and plasma of human blood. J Biol Chem 172:471-476
29. Smith P, Krohn R, Hermanson G, Mallia A, Gartner F, Provenzano M, Fujimoto E, Goeke N, Olson B, Klenk D (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
30. Stratton LP, Rudolph AS, Knoll WKJ, Bayne S, Farmer MC. (1988) The reduction of methemoglobin levels by antioxidants. Hemoglobin 12:353-368
31. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PHThJ, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68:2-9
32. Vaisman A, Lim S, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, Chaney SG (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity of translesion synthesis past platinum-DNA adducts. Biochemistry 38:11026-11039
33. Wei M, Cohen SM, Silverman AP, Lippard SJ (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 276:38774-38780